Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines

Molecular Therapy

Volumn 15, Issue 5, 2007, Pages 971-980

  Koya, Richard C ^a   Kimura, Takahiro ^a   Ribas, Antoni ^a   Rozengurt, Nora ^a   Lawson, Gregory W ^a   Faure Kumar, Emmanuelle ^a   Wang, He Jing ^a   Herschman, Harvey ^a   Kasahara, Noriyuki ^a   Stripecke, Renata ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; LENTIVIRUS VECTOR; MELAN A; RECOMBINANT GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL STIMULATION; CELL TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DRUG POTENCY; ENGRAFTMENT; EX VIVO STUDY; GENETIC ENGINEERING; GENETIC TRANSDUCTION; IN VIVO STUDY; LONG TERM CARE; LYMPHATIC DRAINAGE; MELANOMA; MOUSE; NONHUMAN; PARACRINE SIGNALING; PHENOTYPE; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGENS, CD; ANTIGENS, NEOPLASM; BONE MARROW CELLS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; DENDRITIC CELLS; FLOW CYTOMETRY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-4; LENTIVIRUS; LUCIFERASES; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TRANSFECTION;

MUS;

EID: 34247189774     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.sj.6300126     Document Type: Article

References (20)

1. Banchereau, J and Steinman, RM (1998). Dendritic cells and the control of immunity. Nature 392: 245-252.
2. Antonia, S, Mule, JJ and Weber, JS (2004). Current developments of Immunotherapy in the clinic. Curr Opin Immunol 16: 130-136.
3. Inaba, K, Steinman, RM, Pack MW, Aya, H, Inaba, M, Sudo, T et al. (1992). Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 175: 1157-1167.
4. Sallusto, F and Lanzavecchia, A (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179: 1109-1118.
5. Lutz, MB, Suri, RM, Niimi, M, Ogilvie, AL, Kukutsch, NA, Rossner, S et al. (2000). Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 30: 1813-1822.
6. Ribas, A, Butterfield, LH, Glaspy, JA and Economou, JS (2003). Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21: 2415-2432.
7. Eggert AA, Schreurs, MW, Boerman, OC, Oyen, WJ, de Boer, AJ, Punt, CJ et al. (1999). Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 59: 3340-3345.
8. Morse, MA, Coleman, RE, Akabani, G, Niehaus, N, Coleman, D and Lyerly, HK (1999). Migration of human dendritic cells after Injection in patients with metastatic malignancies. Cancer Res 59: 56-58.
9. + monocytes generates dendritic cells in vitro. Hum Gene Ther 15: 733-748.
10. + cells in cancer patients. Cancer Res 60: 1934-1941.
11. Basak SK, Harui, A, Stolina, M, Sharma, S, Mitani, K, Dubinett, SM et al. (2002). Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood 99: 2869-2879.
12. Dranoff, G, Jaffee, E, Lazenby, A, Golumbek, P, Levitsky, H, Brose, K et al. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543.
13. Stripecke, R, Skelton, DC, Pattengale, PK, Shimada, H and Kohn, DB (1999). Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia. Hum Gene Ther 10: 2109-2122.
14. Hu, HM, Urba, WJ and Fox, BA (1998). Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol 161: 3033-3041.
15. Klein, C, Bueler, H and Mulligan, RC (2000). Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 191: 1699-1708.
16. Stripecke, R, Koya, RC, Ta, HQ Kasahara, N and Levine, AM (2003). The use of lentiviral vectors in gene therapy of leukemia: Combinatorial gene delivery of immunomodulators into leukemia cells by state-of-the-art vectors. Blood Cells Mol Dis 31: 28-37.
17. Ribas, A, Butterfield, LH, McBride, WH, Jilani, SM, Bui, LA, Vollmer, CM et al. (1997). Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res 57: 2865-2869.
18. Sastry, L, Johnson, T, Hobson, MJ, Smucker, B and Cornetta, K (2002). Titering lentiviral vectors: Comparison of DNA, RNA and marker expression methods. Gene Ther 9: 1155-1162.
19. Prins, RM, Odesa, SK and Liau, LM (2003). Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 63: 8487-8491.
20. Ribas, A, Butterfield, LH, Hu, B, Dissette, VB, Chen, AY, Koh, A et al. (2000). Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother 23: 59-66.